Abstract: An electromechanical stimulation system for treating tinnitus comprising a proximal unit (10), configured to be placed proximate to a user's ear (1), and an input interface (50) configured to be operated by the user. The proximal unit comprises an electromechanical device (30) configured to transmit mechanical vibrations (35) with predetermined frequency (f), intensity (A) and waveform, to tissues proximate to the user's ear; a control unit (20), configured to actuate the electromechanical device in such a way that the frequency, the intensity and the waveform of the mechanical vibrations can be modified; a transceiver element (40) adapted to receive control signals (45) for the control unit.

Abstract: An electromechanical stimulation system for treating tinnitus comprising a proximal unit (10), configured to be placed proximate to a user's ear (1), and an input interface (50) configured to be operated by the user. The proximal unit comprises an electromechanical device (30) configured to transmit mechanical vibrations (35) with predetermined frequency (f), intensity (A) and waveform, to tissues proximate to the user's ear; a control unit (20), configured to actuate the electromechanical device in such a way that the frequency, the intensity and the waveform of the mechanical vibrations can be modified; a transceiver element (40) adapted to receive control signals (45) for the control unit.

Abstract: The present invention refers to compounds of formula I or II endowed with DDX3 inhibitory activity, relative pharmaceutical compositions and their use as antihyperproliferative agents. (I) or (II).

Abstract: The present invention refers to compounds endowed with RNA helicase DDX3 inhibitory activity of formula I and II and their therapeutic use, in particular for the treatment of viral diseases.

Abstract: The present invention refers to compounds endowed with RNA helicase DDX3 inhibitory activity of formula I and II and their therapeutic use, in particular for the treatment of viral diseases.

Abstract: The invention relates to a method for determining prognosis, predicting or monitoring response to therapy of patients affected by melanoma through the evaluation of the methylation of different genomic DNA sequences, including the Long Interspersed Nucleotide Element-1 (LINE-1) repetitive DNA sequences and/or the concomitant methylation profile of specific groups of genes defined as methylation signature.

Abstract: The present invention concerns an automatic method for measuring a baby's cry, comprising the following step: A. having N samples ?(i), for i=O, 1, . . . , (N?1), of an acoustic signal p(t) representing the cry, sampled at a sampling frequency? for a period of duration P; the method being characterised in that it assigns a score PainScore to the acoustic signal p(t) by means of a function AF of one or more acoustic parameters selected from the group comprising: —a root-mean-square or rms value prms of the acoustic signal p(t) in the period P; —a fundamental or pitch frequency F0 of the acoustic signal p(t), i.e. the minimum frequency at which a peak in the spectrum of the acoustic signal p(t) occurs in the period P; and—a configuration of amplitude and frequency modulation of the acoustic signal p(t) in the period P. The invention further concerns the apparatus performing the method.